Evidence map›Paper›PMID 37191432›Full record

ReviewAging and disease2023

Pharmacological Mechanisms and Clinical Applications of Curcumin: Update.

Min Hao, Yue Chu, Jingxuan Lei, Zhouhui Yao, Pingping Wang, Ziyan Chen, Kuilong Wang, Xianan Sang, Xin Han, Lu Wang and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Aging and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Curcumin Between Pleiotropic Potential and Translational Constraints.International journal of molecular sciences · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Min HaoSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
Yue ChuSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
Jingxuan LeiSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
Zhouhui YaoSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
Pingping WangSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
Ziyan ChenSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
Kuilong WangSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
Xianan SangSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
Xin HanSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
Lu WangSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
Gang CaoSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China.
Zhejiang Chinese Medical University · CNZunyi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Curcumin, a well-known hydrophobic polyphenol extracted from the rhizomes of turmeric (Curcuma longa L.), has attracted great interest in the last ten years due to its multiple pharmacological activities. A growing body of evidence has manifested that curcumin has extensive pharmacological activities including anti-inflammatory, anti-oxygenation, lipid regulation, antiviral, and anticancer with hypotoxicity and minor adverse reactions. However, the disadvantages of low bioavailability, short half-life in plasma, low drug concentration in blood, and poor oral absorption severely limited the clinical application of curcumin. Pharmaceutical researchers have carried out plenty of dosage form transformations to improve the druggability of curcumin and have achieved remarkable results. Therefore, the objective of this review summarizes the pharmacological research progress, problems in clinical application and the improvement methods of curcumin's druggability. By reviewing the latest research progress of curcumin, we believe that curcumin has a broad clinical application prospect for its wide range of pharmacological activities with few side effects. The deficiencies of lower bioavailability of curcumin could be improved by dosage form transformation. However, curcumin in the clinical application still requires further study regarding the underlying mechanism and clinical trial verification.

Identifiers

PMID37191432
PMCPMC10187702
OpenAlexW4312870395

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.